H.C. Wainwright raised the firm’s price target on Arcellx (ACLX) to $95 from $80 and keeps a Buy rating on the shares. The firm says preliminary results from iMMagine-1 are in-line with the initial results from anito-cel in Phase 1 at a similar time point, the analyst tells investors in a research note. The firm says that given this is an early look at the iMMagine-1 study with only half of the patients included in the analysis, it views he results as reinforcing of the anito-cel Phase 1 data and of the positive benefit observed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX:
- Arcellx management to meet virtually with Piper Sandler
- Arcellx to present data for Its Phase 1and iMMagine-1studies to treat RRMM
- Morgan Stanley says anito-cel Phase 2 data next catalyst for Gilead, Arcellx
- Arcellx price target raised to $96 from $81 at Needham
- Arcellx price target raised to $122 from $83 at Stifel